Drug Approvals KG version 0.3.5

<b>Description</b>: The Drug Approvals KG, created and maintained by the Multiomics Provider, provides assertions about regulatory approvals of drug interventions for treating diseases, and observations of off-label use of drug interventions. These assertions and observations are derived through integration of content from DailyMed and the FDA's adverse-event reporting system (FAERS).<b>Example</b>: The Drug Approvals KG shows that leuprolide treats prostate cancer. This assertion is supported by 11 approved New Drug Applications, including NDA019732, and 7 product labels, including LEUPROLIDE ACETATE DEPOT- leuprolide acetate kit. The Drug Approvals KG also shows that risperidone is applied to treat ADHD, off-label. This observation is supported by tens of thousands of case reports in FAERS.The graph currently uses biolink:treats and biolink:applied_to_treat as predicates. Node categories include biolink:SmallMolecule, biolink:ChemicalEntity, and biolink:MolecularMixture for the interventions, and biolink:Disease and biolink:PhenotypicFeature for the conditions.<b>数据集描述</b>: 药物审批知识图谱（Drug Approvals KG）由多组学服务商（Multiomics Provider）创建并维护，其收录了针对疾病治疗的药物干预手段的监管审批断言，以及药物干预手段的超适应症用药观测记录。上述断言与观测记录均整合自每日药品数据库（DailyMed）与美国食品药品监督管理局（FDA）不良事件报告系统（FAERS）的公开内容。<b>示例</b>: 药物审批知识图谱显示，亮丙瑞林（leuprolide）可用于治疗前列腺癌，该断言得到了11项获批的新药申请（New Drug Applications，NDA，含NDA019732）以及7份药品说明书的支持，涉及的说明书包括LEUPROLIDE ACETATE DEPOT及醋酸亮丙瑞林试剂盒。此外，该知识图谱还记录到利培酮（risperidone）被用于超适应症治疗注意缺陷多动障碍（ADHD），该观测结果得到了FAERS收录的数万份病例报告的支撑。当前该知识图谱采用biolink:treats与biolink:applied_to_treat作为语义谓词，其中药物干预手段的节点类别包括biolink:SmallMolecule、biolink:ChemicalEntity及biolink:MolecularMixture，疾病与表型相关节点类别则包括biolink:Disease与biolink:PhenotypicFeature。